Skip to search formSkip to main contentSkip to account menu

bendamustine hydrochloride

Known as: Bendamustine Hydrochloride [Chemical/Ingredient], 2-Benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride, Bendamustin Hydrochloride 
The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine… 
National Institutes of Health

Related topics

Related topics

18 relations

Broader (1)

Antineoplastic Agents, Alkylating

Narrower (6)

CytostasanRibomustinSDX-105SyB L-0501
In BloodNCIt Antineoplastic Agent Terminologyagonistsanalogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
The treatment approaches for Waldenstrom macroglobulinemia (WM) are largely based upon information from single-arm phase II… 
Highly Cited
2018
Highly Cited
2018
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
Abstract Background Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved… 
2016
2016
Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study
Background: Minimal residual disease (MRD) status reflects treatment efficacy and may predict prognosis after first-line therapy… 
Highly Cited
2015
Highly Cited
2015
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Ibrutinib has single agent activity of 22% to 68% in relapsed B-cell non-Hodgkin lymphoma(NHL). This study evaluated the safety… 
2015
2015
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology…
Review
2015
Review
2015
Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.
BACKGROUND Biological treatments, chemoimmunotherapy, and radiotherapy are associated with excellent disease control in both… 
Review
2013
Review
2013
Implementation of an i.v.-compounding robot in a hospital-based cancer center pharmacy.
PURPOSE The implementation of a robotic device for compounding patient-specific chemotherapy doses is described, including a… 
Highly Cited
2010
Highly Cited
2010
Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
BACKGROUND Although initially responsive to therapy, indolent non-Hodgkin lymphomas (NHLs) are generally incurable. Therefore… 
Review
2009
Review
2009
Update in the management of chronic lymphocytic leukemia
Advances in the treatment of chronic lymphocytic leukemia (CLL) have improved initial overall response (OR) rates, complete… 
2007
2007
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors
The present phase I trial was planned to assess the maximum tolerated dose, the dose-limiting toxicity and the pharmacokinetics… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)